Cost-Effectiveness Analysis of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Immunocompromised Adults Diagnosed with Select Cancers in the United States

被引：0
|
作者：
Curran, Desmond [1 ]
Patterson, Brandon [2 ]
Carrico, Justin [3 ]
Salem, Ahmed [4 ]
La, Elizabeth [5 ]
Lorenc, Stephane
Hicks, Katherine [6 ]
Poston, Sara [7 ]
Carpenter, Christopher [8 ]
机构：
[1] GSK, Wavre, Belgium
[2] Janssen Global Serv, Raritan, NJ USA
[3] RTI Hlth Solut, Res Triangle Pk, NC USA
[4] GSK Vaccines, Wavre, Belgium
[5] GSK, Res Triangle Pk, NC USA
[6] RTI HS, Res Triangle Pk, NC USA
[7] GSK, Philadelphia, PA USA
[8] William Beaumont Hosp, Royal Oak, MI 48072 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-31
引用
收藏
页码：S26 / S26
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States
    Ahmed Salem
    Elizabeth M. La
    Desmond Curran
    Brandon J. Patterson
    Justin Carrico
    Stéphane Lorenc
    Katherine A. Hicks
    Sara Poston
    Christopher F. Carpenter
    [J]. PharmacoEconomics - Open, 2023, 7 : 975 - 985
  • [2] Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States
    Salem, Ahmed
    La, Elizabeth M.
    Curran, Desmond
    Patterson, Brandon J.
    Carrico, Justin
    Lorenc, Stephane
    Hicks, Katherine A.
    Poston, Sara
    Carpenter, Christopher F.
    [J]. PHARMACOECONOMICS-OPEN, 2023, 7 (06) : 975 - 985
  • [3] PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF RECOMBINANT ZOSTER VACCINE FOR VACCINATING IMMUNOCOMPROMISED ADULTS AGAINST HERPES ZOSTER IN THE UNITED STATES
    Salem, A.
    Curran, D.
    Carrico, J.
    La, E. M.
    Lorenc, S.
    Hicks, K.
    Poston, S.
    Carpenter, C. F.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S159 - S159
  • [4] Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States
    Curran, D.
    Patterson, B.
    Varghese, L.
    Van Oorschot, D.
    Buck, P.
    Carrico, J.
    Hicks, K.
    Lee, B.
    Yawn, B.
    [J]. VACCINE, 2018, 36 (33) : 5037 - 5045
  • [5] Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States
    Lu, Angela
    Sun, Yuwei
    Porco, Travis C.
    Arnold, Benjamin F.
    Acharya, Nisha R.
    [J]. OPHTHALMOLOGY, 2021, 128 (12) : 1699 - 1707
  • [6] COST-EFFECTIVENESS ANALYSIS OF VACCINATING AGAINST HERPES ZOSTER WITH ADJUVANTED RECOMBINANT ZOSTER VACCINE IN SWITZERLAND
    Nishimwe, M. L.
    Fischer, L.
    Kientsch, U.
    Giannelos, N.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S71 - S71
  • [7] Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    Pellissier, James M.
    Brisson, Marc
    Levin, Myron J.
    [J]. VACCINE, 2007, 25 (49) : 8326 - 8337
  • [8] Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
    Curran, Desmond
    Patterson, Brandon J.
    Van Oorschot, Desiree
    Buck, Philip O.
    Carrico, Justin
    Hicks, Katherine A.
    Lee, Bruce
    Yawn, Barbara P.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 765 - 771
  • [9] Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
    Giannelos, Nikolaos
    Ng, Cheryl
    Curran, Desmond
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [10] Cost-effectiveness analysis of herpes zoster vaccine in adults above 50 in Singapore
    Pan, JiunYit
    Hsu, Tun-Ying
    Johnson, Kelly D.
    Xu, Ruifeng
    Acosta, Camilo J.
    Kawai, Kosuke
    [J]. DERMATOLOGICA SINICA, 2017, 35 (04) : 177 - 181
12345